Wall Street Journal video: Celgene CEO on how we know what stem cells are doing

In this blog we often discuss the fact that more often than not we do not yet know what type of stem cell is going to be the best one for treating any one disease. That has lead us to voice concern about commercial entities that promote many therapies using one cell type, which was addressed in a joint Patient Advisory we posted Monday.

Many commercial stem cell entities however, are trying to help answer that question about which is the right stem cell. This Wall Street Journal video shows a commercial CEO talking about the hard work of doing the science. Bob Hariri is the CEO of Celgene, a company creating products with stem cells found in the placenta after childbirth. While many groups are starting to use placental stem cells for therapies, we really don’t know the full nature of these cells.

Hariri explains that the placenta has a unique relationship with our immune system since it contains foreign genes—those from the father’s sperm—and yet is tolerated by the mother for nine months. His company is trying to harness that unique immunologic ability to treat autoimmune diseases. But first, the firm is trying to understand this unusual cellular skill. In the video he says:

“We are using really rigorous scientific processes to see how the cells work, what makes them different from other cell types and what might be a factor to making them safe.”

In the jargon of science this is work directed to understanding the MOA, or method of action. Until we know the best cell for each patient, our field needs to adhere to the need to understand these MOAs prior to large-scale clinical use of new therapies.

We have a basic rundown of the different cell types posted here.

Don Gibbons

Through their lens: Jacqueline Liu worked on a stem cell patch to repair hearts after heart attack

This summer we’re sponsoring high school interns in stem cell labs throughout California. We asked those students to contribute to our Instagram photos and YouTube videos about life in the lab, and write about their experiences.

Jacqueline Liu did a stem cell research internship this summer in the laboratory of Gerhard Bauer at the University of California, Davis.


Jacqueline Liu submitted this photo of adipocytes differentiated from mesenchymal stem cells to our #CIRMStemCellLab Instagram feed

Before this summer—this year, even—I had never imagined that I would be spending my break time working with stem cells hands on. It simply never occurred to me that I could be this fortunate in obtaining an internship opportunity in the field of stem cell research where there is still so much to be discovered. I have always loved science, and this amazing experience has only led me to appreciate research and its accomplishments even more.

Specifically in my internship, I worked under the direction of my mentor, Dr. Claus Sondergaard, in the cardiac surgery department at the UCD Medical Center’s Institute for Regenerative Cures. At the time, he was working on developing a patch that could be placed onto the heart after a heart attack, hoping improve the condition of patients instead of merely prolonging the deleterious side effects. By seeding mesenchymal stromal cells (MSCs) onto a decellularized matrix, this patch could then regenerate blood vessels and restore blood flow to the heart, compensating for the loss after the heart attack.

For the project I worked on, I helped with reviewing the mechanisms of actions for these mesenchymal stromal cells, which are still rather mysterious. While we know that they have various healing factors, there is no specific reasoning other than the secreted factors. Even so, which factor? Why? At what levels? The ELISA assay I performed involved IL-8, a human protein often found in saliva. Through this immunoassay, I was able to compare the secretion levels of IL8 between the MSCs that were originally seeded on matrix and those that were grown on plastic. As a result, I found that the cells on matrix emitted almost 40 times as much protein as the ones on plastic, showing another advantage of using a matrix rather than only injecting the cells onto the site of injury. Seemingly, the MSCs prefer the matrix environment with something to bind to rather than floating freely.

Besides this assay, I mainly worked on characterizing MSCs according to the three criteria of plastic adherence, aptitude for trilineage differentiation, and display of certain antigen markers on the cell surface. To do so, I grew MSCs in a plastic flask and examined them under a microscope, thus displaying the cells’ adherence to plastic. Next, I differentiated the MSCs into osteocytes, adipocytes, and chondrocytes to satisfy the criterion of trilineage differentiation. Lastly, I performed flow cytometry to select for certain cell markers, completing the process and confirming that these cells were indeed mesenchymal stem cells and usable for future study.

Although I did not directly interact with in vivo experiments of MSCs on matrix or in the heart, I performed many of the basic duties needed before using these stem cells during in the large animal model or clinical trials. It is important to first characterize the cells and examine ones from different donors in order to consider which cells may be better for trials and hopefully treatments in the future. By doing these assays and characterizations I feel like I was able to contribute to the overall project and make a difference, though most likely minute, in the stem cell field.

Jacqueline Liu

Jacqueline sent us this video of her experience: